#BiliarytractCancer
LightNews LightNews
gastroagi.bsky.social
ASCOT shows that the survival benefit of adjuvant S-1 after BTC surgery remained durable with longer follow-up.

#GIOncology #BiliaryTractCancer #ClinicalEvidence #Gastroenterology #MedSky
September 28, 2026 at 7:10 AM
lorenzarimassa.bsky.social
So grateful to have worked with this amazing group of friends and colleagues on #research priorities for #systemic therapies for #cholangiocarcinoma #biliarytractcancer #CCA #BTC @cholangiocarcinoma.bsky.social #HUNIMED #HUMANITAS @rachnatshroff.bsky.social @ardamanshergill.bsky.social
April 11, 2025 at 2:22 AM
vcclibrary.bsky.social
Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for #BiliaryTractCancer. ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
September 25, 2026 at 9:32 AM
mskdeptofmed.bsky.social
Starting at 11:30 a.m. PST: #GI25 poster sessions! Stop by the West Hall for #pancreaticcancer and #biliarytractcancer advances by James Harding, Eileen O'Reilly, Rohit Thummalapalli, and Layal Al Mahmasani! @mskcancercenter.bsky.social @ascocancer.bsky.social

bit.ly/3WB5q7J
January 24, 2025 at 6:20 PM
oncodaily.bsky.social
Five papers suggested by Arndt Vogel
@arndtvogel.bsky.social

oncodaily.com/science/arnd...

#BiliarytractCancer #Cancer #Cholangiocarcinoma #ESMO #ClinicalPracticeGuideline #HepatocellularCarcinoma #OncoDaily #Oncology #PancreaticCancer
Five papers suggested by Arndt Vogel - OncoDaily
Five papers suggested by Arndt Vogel / Amanda L. Blackford, Arndt Vogel, Biliary tract cancer, cancer, cholangiocarcinoma, Daniel Q. Huang, ESMO Clinical
oncodaily.com
December 26, 2024 at 8:44 PM
oncodaily.bsky.social
New Survival Benchmark for People Living with Advanced Biliary Tract Cancer - Lorenza Rimassa
@lorenzarimassa.bsky.social

oncodaily.com/science/lore...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #BiliaryTractCancer
Lorenza Rimassa: New Survival Benchmark for People Living with Advanced Biliary Tract Cancer - OncoDaily
Lorenza Rimassa: New Survival Benchmark for People Living with Advanced Biliary Tract Cancer / Aiwu Ruth He, Aleksandra Kuzko, Arndt Vogel, Biliary tract
oncodaily.com
July 14, 2025 at 11:45 PM
mskdeptofmed.bsky.social
James J. Harding, MD, found zanidatamab led to ctDNA reductions in most patients with HER2+ #biliarytractcancer after 2 cycles, with 94% concordance between IHC 3+ and HER2 gene amplification in tumors. @mskcancercenter.bsky.social #ASCO25
Learn more: bit.ly/4jAUBvc
June 2, 2025 at 7:09 PM
peerview.bsky.social
Night 1️⃣ of PeerView symposia at #GI25 was a success! 🎉 Congrats to Drs. Ghassan Abou-Alfa, Lipika Goyal, James J. Harding & Arndt Vogel on an amazing #BiliaryTractCancer session.

📌Tonight: HER2+ GI cancers & colorectal cancer—stay tuned!

Visit bit.ly/ASCOGIsky for more info!
#Oncsky #Medsky
January 24, 2025 at 11:28 AM
myesmo.bsky.social
#ESMOGI25: Encouraging activity reported with olaparib in patients with advanced pretreated #BiliaryTractCancer and aberrant #HRR mutations, suggesting #PrecisionOncology may be a rational approach in this setting. Read more in the #ESMODailyReporter
🔗 buff.ly/i1NUMC9
July 5, 2025 at 7:30 AM
onco404.bsky.social
A real-world study from France highlights zanidatamab as a promising therapy for HER2-positive advanced biliary tract cancers ( #BTC ).

@eortc.org #EJC

#Onco404 #Cancer #Kanser #PrecisionMedicine #KişiyeÖzelTedavi #MedSky #OncSky #BiliaryTractCancer #HER2 #TargetedTherapy #MonoclonalAntibody
April 27, 2025 at 9:02 AM
oncodaily.bsky.social
FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov

oncodaily.com/blog/215120

#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
Chris De Savi: FDA Novel Drug approvals in 2024 - OncoDaily
Chris De Savi: FDA Novel Drug approvals in 2024 / Acoramidis, acute leukemia, arrhythmia management, Biliary tract cancer, cancer, Cancer Cell, cell growth,
oncodaily.com
January 2, 2025 at 5:31 PM
peerview.bsky.social
Bolster your skills with #immunotherapy platform selection when treating patients with #biliarytractcancer. Arndt Vogel, MD, PhD, provides an expert overview in this new microlearning activity t.co/TiGok4nvfV
Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease
November 22, 2024 at 4:49 PM
cancer-control.bsky.social
Single-centre (@petermaccc.bsky.social) real-world data on #BiliaryTractCancer: 1st line gem/cis+ICI yields outcomes comparable to pivotal trials. ECOG & albumin predict survival. #HER2 amp = worse OS; dMMR & #BRCA = trend toward improved OS. Study highlights importance of molecular profiling.
November 11, 2025 at 4:00 PM
lorenzarimassa.bsky.social
Ready for the @cholangiocarcinoma.bsky.social consensus conference on research priorities for #cholangiocarcinoma #CCA #biliarytractcancer #BTC #HumanitasUniversity #HUMANITASResearchHospital
April 9, 2025 at 3:55 PM
oncodaily.bsky.social
The Role of cfDNA in Biliary Tract Cancer: Clinical and Prognostic Perspectives

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #cfDNA #BiliaryTractCancer #BTC
The Role of cfDNA in Biliary Tract Cancer: Clinical and Prognostic Perspectives - OncoDaily
Explores whether cfDNA is a game changer in BTC, highlighting its clinical value, high concordance with tissue testing, and prognostic insights.
oncodaily.com
September 21, 2025 at 6:10 PM
digestivecancerseu.bsky.social
On the final day of the #BiliaryTractCancer (BTC) Awareness Month, we are sharing a quote from Elisabeth Baucells Molera, the president of the Spanish Biliary Tract Cancer organisation, ATUVIBI.
February 28, 2025 at 7:45 AM
tamedoncol.bsky.social
A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection.
buff.ly/6PIVm3G
#Cholangiocarcinoma #GeriatricOncology
May 22, 2026 at 7:01 AM
cholangiocarcinoma.bsky.social
Join us today in San Francisco at 6:00 PM PST for our #BiliaryTractCancer symposium, live in-person and virtual, during #ASCOGI2025. Share your questions in advance to @peerview.bsky.social View and get answers from our expert panel! bit.ly/Biliary-SF25T
MDADI
MDADI
bit.ly
January 23, 2025 at 3:07 PM
jamaoncology.com
Among patients with advanced #BiliaryTractCancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy ja.ma/4ygxazN
RCT: Durvalumab + Chemo for advanced biliary tract cancer. 685 participants (median age 64) were randomized. Findings show Durvalumab + GemCis (341) significantly improved OS vs. Placebo + GemCis (344). HR 0.75. Graph shows survival curves.
July 10, 2026 at 3:30 PM
onclive.bsky.social
Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline @mskcancercenter.bsky.social #biliarytractcancer #MedTwitter www.onclive.com/view/zanidat...
Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline
James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.
www.onclive.com
December 12, 2024 at 4:45 PM
livermd.bsky.social
The road to #GI23 is long and arduous but ultimately worth it. I don’t think I’ve had an on time flight in 6 months. Can you tell I look thrilled? @ASCO @ASCOPost #HCC #biliarytractcancer
December 2, 2024 at 9:57 PM
thecancersurvivorsclub.com
Encouraging Phase 3 results in advanced biliary tract cancer. Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in a first-line trial.

www.prnewswire.com/news-release...

#BiliaryTractCancer #CancerResearch #TCSC
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that a pre-specified interim analysis assessed by the Independent Data...
www.prnewswire.com
August 26, 2026 at 8:39 AM
livermd.bsky.social
A whole lot happening in the #biliarytractcancer space. A must attend for all interested in hepato-oncology ⁦@MiteshBorad⁩
11/4/22, 10:45 AM — Novel Targeted and Combination Therapies for #Cholangiocarcinoma #TLM22
December 2, 2024 at 10:49 PM
onjcri.org.au
Results from ONJCRI’s MoST-CIRCUIT clinical trial suggest that combination immunotherapy with nivolumab and ipilimumab is a promising avenue for hard-to-treat gallbladder cancer patients.

➡️ https://ow.ly/RLX450YT3pI

#ClinicalTrials #GallbladderCancer #BiliaryTractCancer #immunotherapy
May 1, 2026 at 2:30 AM
oncologynurseadv.bsky.social
In fit older patients with advanced #biliarytractcancer, the combination chemotherapeutic regimen of GEM+CDDP+S-1 is associated with longer PFS compared with that of GEM+CDDP. Published in @gastroadvisor.bsky.social.

https://bit.ly/3KW5UlP
Optimal Systemic Chemotherapy Varies Widely in Advanced Biliary Tract Cancer - Oncology Nurse Advisor
Researchers evaluated overall and progression-free survival among older adults with advanced biliary tract cancer who received combination chemotherapy.
bit.ly
October 18, 2025 at 8:41 PM